| 元智大學 |
Apr-21 |
Associations between Lifestyle Habits, Perceived Symptoms and Gastroesophageal Reflux Disease in Patients Seeking Health Check-Ups
|
Chang, C.-H.; Chen, T.-H.; Chiang, L.; Hsu, C.-L.; Yu, H.-C.; Mar, G.-Y.; Ma, C.-C. |
| 國立成功大學 |
2023 |
User-centered empathy design: a prototype of school-age children learning aids system
|
Yu, H.-C.;Chou, Chou C.-J.;Luh, D.-B.;Hsieh, M.-H. |
| 臺大學術典藏 |
2022-09-21T08:16:44Z |
Safeguarding medication use through interprofessional collaboration: Example of inpatient medication management and use
|
Yu H.-C.; Chen Y.-J.; Wu R.-S.; YUNN-FANG HO |
| 臺大學術典藏 |
2022-09-15T05:50:19Z |
Cutaneous presentation of disseminated cytomegalovirus infection in a non-transplant patient with hematological malignancy: A case report
|
Yu H.-C.; WANG-DA LIU; Kuo P.-H.; Lin C.-C.; Wu U.-I.; Saranathan. M. |
| 臺大學術典藏 |
2022-07-15T08:17:35Z |
Risk of skin cancer in patients with pterygium: A nationwide population-based cohort study in Taiwan
|
Yu H.-C.; Lin C.-L.; Chen Z.T.-Y.; FUNG-RONG HU; Sung F.-C.; Wang I.-J. |
| 臺大學術典藏 |
2022-03-04T06:53:47Z |
Design and implementation of mobile electronic medication administration record
|
Hsieh S.-H.; Hou I.-C.; CHING-TING TAN; Shen P.-C.; Yu H.-C.; Hsieh S.-L.; Cheng P.-H.; Lai F. |
| 臺大學術典藏 |
2022-03-04T06:53:42Z |
Improving inpatient fall prevention strategies using interactive data repository information system
|
Chen L.; Yu H.-C.; Lee H.-C.; Chung Y.; Shang R.-J.; Liu H.-Y.; CHING-TING TAN; Lai F. |
| 臺大學術典藏 |
2022-02-15T05:45:01Z |
Cutaneous presentation of disseminated cytomegalovirus infection in a non-transplant patient with hematological malignancy: A case report
|
Yu H.-C.; Liu W.-D.; Kuo P.-H.; Lin C.-C.; UN-IN WU |
| 臺大學術典藏 |
2022-02-14T07:10:52Z |
Metabolic risk factors are associated with non-hepatitis B non-hepatitis C hepatocellular carcinoma in Taiwan, an endemic area of chronic hepatitis B
|
Huang S.-F.; Chang I.-C.; Hong C.-C.; Yen T.-C.; Chen C.-L.; Wu C.-C.; Tsai C.-C.; Ho M.-C.; Lee W.-C.; Yu H.-C.; Shen Y.-Y.; Eng H.-L.; Wang J.; Tseng H.-H.; YUNG-MING JENG; Yeh C.-T.; Chen C.-L.; Chen P.-J.; Liaw Y.-F. |
| 臺大學術典藏 |
2022-01-25T03:25:14Z |
The Hepatitis Viral Status in Patients with Hepatocellular Carcinoma: A Study of 3843 Patients from Taiwan Liver Cancer Network
|
Chang I.-C.; Huang S.-F.; Chen P.-J.; CHI-LING CHEN; Chen C.-L.; Wu C.-C.; Tsai C.-C.; Lee P.-H.; Chen M.-F.; Lee C.-M.; Yu H.-C.; Lo G.-H.; Yeh C.-T.; Hong C.-C.; Eng H.-L.; Wang J.; Tseng H.-H.; Hsiao C.-H.; Wu H.-D.I.; Yen T.-C.; Liaw Y.-F. |
| 臺大學術典藏 |
2022-01-25T03:25:06Z |
Metabolic risk factors are associated with non-hepatitis B non-hepatitis C hepatocellular carcinoma in Taiwan, an endemic area of chronic hepatitis B
|
Huang S.-F.; Chang I.-C.; Hong C.-C.; Yen T.-C.; CHI-LING CHEN; Wu C.-C.; Tsai C.-C.; Ho M.-C.; Lee W.-C.; Yu H.-C.; Shen Y.-Y.; Eng H.-L.; Wang J.; Tseng H.-H.; Jeng Y.-M.; Yeh C.-T.; Chen C.-L.; Chen P.-J.; Liaw Y.-F. |
| 臺大學術典藏 |
2021-09-14T01:40:05Z |
Association between maternal pre-pregnancy body mass index and breastfeeding duration in Taiwan: A population-based cohort study
|
CHI-NIEN CHEN; Yu H.-C.; Chou A.-K. |
| 臺大學術典藏 |
2021-09-01T01:54:16Z |
Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation
|
Chen K.-F.; Yu H.-C.; Liu T.-H.; Lee S.-S.; Chen P.-J.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:11Z |
CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells
|
Chen K.-F.; Liu C.-Y.; Lin Y.-C.; Yu H.-C.; Liu T.-H.; Hou D.-R.; Chen P.-J.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:10Z |
Bortezomib sensitizes HCC cells to CS-1008, an antihuman death receptor 5 antibody, through the inhibition of CIP2A
|
Chen K.-F.; Yu H.-C.; Liu C.-Y.; Chen H.-J.; Chen Y.-C.; Hou D.-R.; Chen P.-J.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:53:57Z |
Inhibition of Bcl-2 improves effect of LCL161, a SMAC mimetic, in hepatocellular carcinoma cells
|
Chen K.-F.; Lin J.-P.; Shiau C.-W.; Tai W.-T.; Liu C.-Y.; Yu H.-C.; Chen P.-J.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:53:51Z |
Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma
|
Yu H.-C.; Chen H.-J.; Chang Y.-L.; Liu C.-Y.; Shiau C.-W.; ANN-LII CHENG; Chen K.-F. |
| 臺大學術典藏 |
2021-09-01T01:53:50Z |
Cancerous Inhibitor of Protein Phosphatase 2A Mediates Bortezomib-Induced Autophagy in Hepatocellular Carcinoma Independent of Proteasome
|
Yu H.-C.; Hou D.-R.; Liu C.-Y.; Lin C.-S.; Shiau C.-W.; ANN-LII CHENG; Chen K.-F. |
| 臺大學術典藏 |
2021-08-31T06:29:33Z |
Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen
|
Chen I.-C.; Hsiao L.-P.; Huang I.-W.; Yu H.-C.; Yeh L.-C.; Lin C.-H.; Wei-Wu Chen T.; ANN-LII CHENG; Lu Y.-S. |
| 臺大學術典藏 |
2021-08-16T03:26:38Z |
Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen
|
I-CHUN CHEN; Hsiao L.-P.; Huang I.-W.; Yu H.-C.; Yeh L.-C.; Lin C.-H.; Wei-Wu Chen T.; Cheng A.-L.; Lu Y.-S. |
| 臺大學術典藏 |
2021-07-16T06:18:16Z |
Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation
|
Chen K.-F.; Yu H.-C.; Liu T.-H.; SHOEI-SHENG LEE; Chen P.-J.; Cheng A.-L. |
| 臺大學術典藏 |
2021-07-06T02:04:11Z |
STAT3 mediates regorafenib-induced apoptosis in hepatocellular carcinoma
|
Tai W.-T.; Chu P.-Y.; Shiau C.-W.; Chen Y.-L.; Li Y.-S.; Hung M.-H.; Chen L.-J.; PEI-LUNG CHEN; Su J.-C.; Lin P.-Y.; Yu H.-C.; Chen K.-F. |
| 臺大學術典藏 |
2021-07-03T03:34:45Z |
Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation
|
Chen K.-F.; Yu H.-C.; Liu T.-H.; Lee S.-S.; PEI-JER CHEN; Cheng A.-L. |
| 臺大學術典藏 |
2021-07-03T03:34:40Z |
CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells
|
Chen K.-F.; Liu C.-Y.; Lin Y.-C.; Yu H.-C.; Liu T.-H.; Hou D.-R.; PEI-JER CHEN; Cheng A.-L. |
| 臺大學術典藏 |
2021-07-03T03:34:38Z |
Bortezomib sensitizes HCC cells to CS-1008, an antihuman death receptor 5 antibody, through the inhibition of CIP2A
|
Chen K.-F.; Yu H.-C.; Liu C.-Y.; Chen H.-J.; Chen Y.-C.; Hou D.-R.; PEI-JER CHEN; Cheng A.-L. |
